Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
Parth Vashi,1,* Katharine Batt,2,* Robert Klamroth,3 Maria Elisa Mancuso,4 Renata Majewska,5,6 Andreas Tiede,7 Lorenzo Giovanni Mantovani8,9 1US Data Generation and Observational Studies, Bayer Corporation, Whippany, NJ, USA; 2Department of Internal Medicine, Section on Hematology/Me...
Main Authors: | Vashi P, Batt K, Klamroth R, Mancuso ME, Majewska R, Tiede A, Mantovani LG |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-11-01
|
Series: | Journal of Blood Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/indirect-treatment-comparison-of-damoctocog-alfa-pegol-versus-turoctoc-peer-reviewed-fulltext-article-JBM |
Similar Items
-
Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
by: Ezio Zanon
Published: (2023-08-01) -
Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
by: Klamroth R, et al.
Published: (2021-11-01) -
Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
by: Napolitano M, et al.
Published: (2021-01-01) -
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
by: Steven R. Lentz, et al.
Published: (2022-02-01) -
Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01)